Protagenic Therapeutics, Inc, 149 5th Ave, Rm 500, New York, NY 10010, US

Synaptogenix, Inc is a pioneering company based in New York, NY, dedicated to discovering restorative and innovative therapeutics for patients suffering from neurodegenerative diseases and developmental disorders. With a mission to achieve clinically meaningful restoration of cognitive function and regeneration of cerebral connections, Synaptogenix has successfully completed two Phase II pilot study trials and established partnerships with prestigious institutions such as the National Cancer Institute, National Institute of Health, and National Institute of Aging. Led by a management team with over 30 years of experience, the company has secured significant funding and is actively working on indications including Alzheimer's disease, Fragile X Syndrome, Autism, Multiple Sclerosis, Parkinson's Disease, Traumatic Brain Injury, and Stroke. Synapses, the tiny connectors in the brain that allow neurons to communicate, play a crucial role in cognitive functioning. Synaptic loss or dysfunction can lead to impaired cognition and neurodegenerative diseases like Alzheimer's. Synaptogenix's research focuses on the promotion of neuronal health and synaptic regeneration, particularly through the use of Bryostatin, a protein kinase C activator. Their groundbreaking work has shown promising results in restoring hippocampal synapses, improving spatial learning and memory, and reducing amyloid levels associated with Alzheimer's disease. Through their dedication to scientific advancement and collaboration with leading institutions, Synaptogenix aims to rebuild connections and restore lives for individuals affected by these debilitating conditions.Generated from the website

Edward Longley - Sotheby's Int'l Realty

Raymond Moore - Core Real Estate

J United

Ahi